This presentation describes the best ways to achieve a harmonized investment strategy in manufacturing capacity and construct a robust supply chain in the pharmaceutical manufacturing landscape. It delves into the allogeneic manufacturing process, addressing scalability considerations and optimizing patient supply. The session explores diverse approaches to manufacturing autologous, allogeneic, and “next-generation” autologous therapies. A significant aspect covered is the impact of donor variability, identified as the primary source of variability for cell therapies, and strategies for characterizing and accommodating this variability. The presentation concludes with an examination of key challenges and areas for improvement through insights gained from different case studies. In this session, you will find out more about

• Successful strategies for achieving a balanced investment in manufacturing capacity and building a resilient supply chain
• How to optimize allogeneic manufacturing processes for enhanced patient supply
• How to addressing the challenges associated with donor variability and exploring areas for improvement through case studies.